| 000 | 01694 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514194348.0 | ||
| 264 | 0 | _c20040920 | |
| 008 | 200409s 0 0 eng d | ||
| 022 | _a0009-9104 | ||
| 024 | 7 |
_a10.1111/j.1365-2249.2004.02523.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLin, A W | |
| 245 | 0 | 0 |
_aCD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. _h[electronic resource] |
| 260 |
_bClinical and experimental immunology _cAug 2004 |
||
| 300 |
_a408-16 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnnexin A5 _xmetabolism |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 |
_aCD3 Complex _xblood |
| 650 | 0 | 4 |
_aCD56 Antigen _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 |
_aKiller Cells, Natural _xdrug effects |
| 650 | 0 | 4 | _aLymphocyte Activation |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPolyethylene Glycols |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aUp-Regulation |
| 700 | 1 | _aGonzalez, S A | |
| 700 | 1 | _aCunningham-Rundles, S | |
| 700 | 1 | _aDorante, G | |
| 700 | 1 | _aMarshall, S | |
| 700 | 1 | _aTignor, A | |
| 700 | 1 | _aHa, C | |
| 700 | 1 | _aJacobson, I M | |
| 700 | 1 | _aTalal, A H | |
| 773 | 0 |
_tClinical and experimental immunology _gvol. 137 _gno. 2 _gp. 408-16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2249.2004.02523.x _zAvailable from publisher's website |
| 999 |
_c14972939 _d14972939 |
||